Comorbidities in COPD;Comorbilidades de la EPOC

Archivos de Bronconeumologia

Volumn 46, Issue SUPPL.11, 2010, Pages 20-25

  de Miguel Díez, Javier ^a   García, Teresa Gómez ^a   Maestu, Luis Puente ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

COPD Cardiovascular disease Respiratory infection Lung cancer Skeletal muscle dysfunction Diabetes mellitus Osteoporosis Anemia Psychiatric disorders

Indexed keywords

ARTICLE; CAUSAL ATTRIBUTION; CAUSE OF DEATH; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; COMORBIDITY; COST OF ILLNESS; DEPRESSION; DIABETES MELLITUS; DISEASE ASSOCIATION; HEART FAILURE; HUMAN; HYPERTENSION; INFLAMMATORY DISEASE; ISCHEMIC HEART DISEASE; LUNG CANCER; OSTEOARTHRITIS; PROGNOSIS; PULMONARY HYPERTENSION; RESPIRATORY FAILURE; RESPIRATORY TRACT INFECTION;

ANEMIA; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; COMORBIDITY; DEPRESSION; DIABETES MELLITUS; HUMANS; HYPERTENSION; INFECTION; INFLAMMATION; MUSCLE WEAKNESS; NEOPLASMS; OSTEOPOROSIS; PREVALENCE; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKING;

EID: 79851504515     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1016/S0300-2896(10)70058-2     Document Type: Article

References (94)

1. Pena X., Van Den Eynde E., Mena E., Recio J. EPOC y enfermedad cardiovascular. Rev Clin Esp 2007, 207(Supl 1):14-21.
2. Fabbri L.M., Ferrari R. Chronic disease in the elderly: back to the future of internal medicine. Breathe 2006, 3:40-49.
3. Álvarez-Sala J.L., De Miguel Díez J. EPOC y comorbilidad: una visión global. Introducción. Arch Bronconeumol 2009, 45(Supl 4):1.
4. Mapel D.W., Hurley J.S., Frost F.J., Petersen H.V., Picchi M.A., Coultas D.B. Health care utilization in chronic obstructive pulmonary disease: a case-control study in a health maintenance organization. Arch Intern Med 2000, 160:2653-2658.
5. Van Manen J.G., Bindels P.J., IJzermans C.J., Van der Zee J.S., Bottema B.J., Schade E. Prevalence of comorbidity in patients with a chronic airway obstruction and controls over the age of 40. J Clin Epidemiol 2001, 54:287-293.
6. De Miguel Díez J., Izquierdo Alonso J.L., Molina París J., Bellón Cano J.M., Rodríguez González-Moro J.M., De Lucas Ramos P. Factores determinantes de la prescripción farmacológica en los pacientes con EPOC estable. Resultados de un estudio multicéntrico español (IDENTEPOC). Arch Bronconeumol 2005, 41:63-70.
7. Sidney S., Sorel M., Quesenberry C.P.Jr., DeLuise C., Lanes S., Eisner M.D. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest 2005, 128:2068-2075.
8. Carrasco Garrido P., De Miguel Díez J., Rejas Gutiérrez J., Martín Centeno A., Gobartt Vázquez E., Gil de Miguel A., et al. Negative impact of chronic obstructive pulmonary disease on the health-related quality of life of patients. Results of the EPIDEPOC study. Health and Quality of Life Outcomes 2006, 4:31.
9. De Miguel Díez J. Comorbilidades en la EPOC en atención primaria 2009, Gráficas ENAR, Madrid.
10. Almagro P., Calbo E., Ochoa de Echaguen A., Barreiro B., Quintana S., Heredia J.L., et al. Mortality after hospitalization for COPD. Chest 2002, 121:1441-1448.
11. Antonelli Incalzi R., Fuso L., De Rosa M., Forastiere F., Rapiti E., Nardecchia B., et al. Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur Respir J 1997, 10:2794-2800.
12. Holguin F., Folch E., Redd S.C., Mannino D.M. Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001. Chest 2005, 128:2005-2011.
13. Almagro P. Factores pronósticos en la EPOC. El papel de la comorbilidad. Rev Clin Esp 2007, 207(Supl 1):8-13.
14. Mannino D.M., Watt G., Hole D., Gillis C., Hart C., McConnachie A., et al. The natural history of chronic obstructive pulmonary disease. Eur Respir J 2006, 27:627-643.
15. Calverley P.M.A., Anderson J.A., Celli B., Ferguson G.T., Jenkins C., Jones P.W., et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Eng J Med 2007, 356:775-789.
16. Barnes P.J., Celli B.R. Systemic manifestations and comorbidities of COPD. Eur Respir J 2009, 33:1165-1185.
17. De Miguel Díez J., Carrasco Garrido P., Rejas Gutiérrez J., Martín Centeno A., Gobartt-Vázquez E., Hernández Barrera V., et al. The influence of heart disease on characteristics, quality of life, use of health resources, and costs of COPD in primary care settings. BMC Cardiovasc Disord 2010, 10:8.
18. Falk J.A., Kadiev S., Criner G.J., Scharf S.M., Minai O.A., Díaz P. Cardiac disease in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008, 5:543-548.
19. Sin D.D., Man S.F. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003, 107:1514-1519.
20. Antonelli-Incalzi R., Fuso L., De Rosa M., Forastiere F., Rapiti E., Nardecchia B., et al. Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur Respir J 1997, 10:2794-2800.
21. Ridker P.M. Evaluating novel cardiovascular risk factors: can we better predict heart attacks?. Ann Intern Med 1999, 130:933-937.
22. Danesh J., Whincup P., Walker M., Lennon L., Thomson A., Appleby P., et al. Low-grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 2000, 321:199-204.
23. Ridker P.M. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003, 107:363-369.
24. Wedzicha J.A., Seemungal T.A., MacCallum P.K., Paul E.A., Donaldson G.C., Bhowmik A., et al. Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6. Thromb Haemost 2000, 84:210-215.
25. Gan W.Q., Man S.F., Senthilselvan A., Sin D.D. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004, 59:574-580.
26. Man S.F., Connett J.E., Anthonisen N.R., Wise R.A., Tashkin D.P., Sin D.D. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax 2006, 61:849-853.
27. Pearson T.A., Mensah G.A., Alexander R.W., Anderson J.L., Cannon R.O., Criqui M., et al. Centers for Disease Control and Prevention; American Heart Association Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003, 107:499-511.
28. Ridker P.M., Rifai N., Pfeffer M., Sacks F., Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 1999, 100:230-235.
29. Ridker P.M., Rifai N., Lowenthal S.P. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 2001, 103:1191-1193.
30. Albert M.A., Danielson E., Rifai N., Ridker P.M. Effect of statin therapy on C-reactive protein levels: the Pravastatin Inflammation/CRP Evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001, 286:64-70. PRINCE Investigators.
31. Soyseth V., Brekke P., Smith P., Omland T. Statin use is associated with reduced mortality in COPD. Eur Respir J 2007, 2:279-283.
32. Curkendall S.M., DeLuise C., Jones J.K. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol 2006, 16:63-70.
33. Felker G.M., Petersen J.W., Mark D.B. Natriuretic peptides in the diagnosis and management of heart failure. CMAJ 2006, 7:175-611.
34. Maisel A.S., McCord J., Nowak R.M., Hollander J.E., Wu A.H., Duc P., et al. Breathing Not Properly Multinational Study Investigators Bedside B-type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study. J Am Coll Cardiol 2003, 41:2010-2017.
35. Salpeter S., Ormiston T., Salpeter E. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest 2004, 125:2309-2321.
36. Souverein P.C., Berard A., Van Staa T.P., Cooper C., Egberts A.C.G., Leufkens H.G.M., et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart 2004, 90:859-865.
37. McCord J., Borzak S. Multifocal atrial tachycardia. Chest 1998, 113:203-209.
38. Kothari S.A., Apiyasawat S., Asad N., Spodick D.H. Evidence supporting a new rate threshold for multifocal atrial tachycardia. Clin Cardiol 2005, 28:561-563.
39. Huerta C., Lanes S.F., García Rodríguez L.A. Respiratory medications and the risk of cardiac arrhythmias. Epidemiology 2005, 16:360-366.
40. Burrows B., Kettel L.J., Niden A.H., Rabinowitz M., Diener C.F. Patterns of cardiovascular dysfunction in chronic obstructive lung disease. N Engl J Med 1972, 286:912-918.
41. Weitzenblum E., Sautegeau A., Ehrhart M., Mammosser M., Hirth C., Roegel E. Long-term course of pulmonary arterial pressure in chronic obstructive pulmonary disease. Am Rev Respir Dis 1984, 130:993-998.
42. Scharf S., Iqbal M., Kellar C., Criner G., Lee S., Fessler H. Hemodynamic characterization of patients with severe emphysema. Am J Respir Crit Care Med 2002, 166:314-322.
43. Chaouat A., Bugnet A., Kadaoui N., Schott R., Enache I., Ducolone A., et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005, 172:189-194.
44. Weitzenblum E., Hirth C., Ducolone A., Mirhom R., Rasaholinjanahary J., Ehrhart M. Prognostic value of pulmonary artery pressure in chronic obstructive pulmonary disease. Thorax 1981, 36:752-758.
45. Oswald-Mammosser M., Weitzenblum E., Quoix E., Chaouat A., Charpentier C., Kessler R. Prognostic factors in COPD patients receiving long-term oxygen therapy: importance of pulmonary artery pressure. Chest 1995, 107:1193-1198.
46. Burgess M.I., Mogulkoc N., Bright-Thomas R.J., Bishop P., Egan J.J., Ray S.G. Comparison of echocardiographic markers of right ventricular function in determining prognosis in chronic pulmonary disease. J Am Soc Echocardiogr 2002, 15:633-639.
47. Leuchte H.H., Baumgartner R.A., Nounou M.E., Vogeser M., Neurohr C., Trautnitz M., et al. Brain natriuretic peptide is a prognostic parameter in chronic lung disease. Am J Respir Crit Care Med 2006, 173:744-750.
48. Weitzenblum E., Sautegeau A., Ehrhart M., Mammosser M., Pelletier A. Long-term oxygen therapy can reverse the progression of pulmonary hypertension in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1985, 131:493-498.
49. Brijker F., Heijdra Y.F., Van den Elshout F.J., Folgering H.T. Discontinuation of furosemide decreases PaCO2 in patients with COPD. Chest 2002, 121:377-382.
50. Huiart L., Ernst P., Suissa S. Cardiovascular morbidity and mortality in COPD. Chest 2005, 128:2640-2646.
51. López García F., Santa-Olalla González M., Custardoy Olavarrieta J. EPOC y enfermedad cerebrovascular. Rev Clin Esp 2007, 207(Supl 1):22-26.
52. Tillie-Leblond I., Marquette C.H., Pérez T., Scherpereel A., Zanetti C., Tonnel A.B., et al. Pulmonary embolism in patients with unexplained exacerbation of chronic obstructive pulmonary disease: prevalence and risk factors. Ann Intern Med 2006, 144:390-396.
53. Rutschmann O.T., Cornuz J., Poletti P.A., Bridevaux P.O., Hugli O., Qanadli S.D., et al. Should pulmonary embolism be suspected in exacerbation of chronic obstructive pulmonary disease?. Thorax 2007, 62:121-125.
54. Barquero Romero J. Comorbilidad infecciosa en el paciente con EPOC. Rev Clin Esp 2007, 207(Supl 1):27-32.
55. Lieberman D., Lieberman D., Gelfer Y., Varshavsky R., Dvoskin B., Leinonen M., et al. Pneumonic vs nonpneumonic acute exacerbations of COPD. Chest 2002, 122:1264-1270.
56. Chatila W.M., Thomashow B.M., Minai O.A., Criner G.J., Make B.J. Comorbidities in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008, 5:549-555.
57. Anthonisen N.R., Connett J.E., Enright P.L., Manfreda J. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002, 166:333-339. Lung Health Study Research Group.
58. Zielinski J., MacNee W., Wedzicha J., Ambrosino N., Braghiroli A., Dolensky J., et al. Causes of death in patients with COPD and chronic respiratory failure. Monaldi Arch Chest Dis 1997, 52:43-47.
59. Lange P., Nyboe J., Appleyard M., Jensen G., Schnohr P. Ventilatory function and chronic mucus hypersecretion as predictors of death from lung cancer. Am Rev Respir Dis 1990, 141:613-617.
60. Wasswa-Kintu S., Gan W.Q., Man S.F., Pare P.D., Sin D.D. Relationship between reduced forced expiratory volume in one second and the risk of lung cancer: a systematic review and meta-analysis. Thorax 2005, 60:570-575.
61. Coronell C., Orozco-Levi M., Méndez R., Ramírez-Sarmiento A., Galdiz J.B., Gea J. Relevance of assessing quadriceps endurance in patients with COPD. Eur Respir J 2004, 24:129-136.
62. Maltais F., Simard A.A., Simard C., Jobin J., Desgagnes P., LeBlanc P. Oxidative capacity of the skeletal muscle and lactic acid kinetics during exercise in normal subjects and in patients with COPD. Am J Respir Crit Care Med 1996, 153:288-293.
63. Gosker H.R., Engelen M.P., Van Mameren H., Van Dijk P.J., Van der Vusse G.J., Wouters E.F., et al. Muscle fiber type IIX atrophy is involved in the loss of fat-free mass in chronic obstructive pulmonary disease. Am J Clin Nutr 2002, 76:113-119.
64. Rana J.S., Mittleman M.A., Sheikh J., Hu F.B., Manson J.E., Colditz G.A., et al. Chronic obstructive pulmonary disease, asthma and risk of type 2 diabetes in women. Diabetes Care 2004, 27:2478-2484.
65. Loukides S., Polyzogopoulos D. The effect of diabetes mellitus on the outcome of patients with chronic obstructive pulmonary disease exacerbated due to respiratory infections. Respiration 1996, 63:170-173.
66. Antonelli I.R., Fuso L., De Rosa M., Forastiere F., Rapiti E., Nardecchia B., et al. Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur Respir J 1997, 10:2794-2800.
67. Chillón Martín M.J., De Miguel Díez J., Ferreira Moreno A., Sánchez Muñoz G. EPOC y alteraciones endocrinometabólicas. Arch Bronconeumol 2009, 45(Supl. 4):42-46.
68. Hotamisligil G.S. The role of TNF alpha and TNF receptors in obesity and insulin resistance. J Intern Med 1999, 245:621-625.
69. Pradhan A.D., Manson J.E., Rifai N., Buring J.E., Ridker P.M. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001, 286:327-334.
70. Chung K.F. Cytokines in chronic obstructive pulmonary disease. Eur Respir J 2001, Suppl 34:50S-59S.
71. Festa A., D'Agostino R.Jr., Tracy R.P., Haffner S.M. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2002, 51:1131-1137.
72. Spranger J., Kroke A., Mohlig M., Hoffmann K., Bergmann M.M., Ristow M., et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based european prospective investigation into cancer and nutrition (EPIC) potsdam study. Diabetes 2003, 52:812-817.
73. Thorand B., Lowel H., Schneider A., Kolb H., Meisinger C., Frohlich M., et al. C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg cohort study, 1984-1998. Arch Intern Med 2003, 163:93-99.
74. Hu F.B., Meigs J.B., Li T.Y., Rifai N., Manson J.E. Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes 2004, 53:693-700.
75. Creutzberg E.C., Casaburi R. Endocrinological disturbances in chronic obstructive pulmonary disease. Eur Respir J 2004, 22(Supl 46):76S-80S.
76. Sevenoaks M.J., Stockley R.A. Chronic obstructive pulmonary disease, inflammation and co-morbidity - a common inflammatory phenotype?. Respir Res 2006, 7:70.
77. Jiménez García R., De Miguel Díez J., Rejas Gutiérrez J., Martín Centeno A., Gobartt Vázquez E., Hernández Barrera V., et al. Health, treatment and health care resources consumption profile among Spanish adults with diabetes and chronic obstructive pulmonary disease. Prim Care Diabetes 2009, 3:141-148.
78. Sánchez-Lora F.J., Amorós Martínez F., García Ordóñez M.A., Custardoy Olavarrieta J. EPOC y transtornos endocrinometabólicos. Rev Clin Esp 2007, 207(Supl 1):33-39.
79. Van Staa T.P., Leufkens H.G., Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002, 13:777-787.
80. Gluck O., Colice G. Recognizing and treating glucocorticoid-induced osteoporosis in patients with pulmonary diseases. Chest 2004, 125:1859-1876.
81. Suissa S., Baltzan M., Kremer R., Ernst P. Inhaled and nasal corticosteroid use and the risk of fracture. Am J Respir Crit Care Med 2004, 169:83-88.
82. Lee T.A., Weiss K.B. Fracture risk associated with inhaled corticosteroid use in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004, 169:855-859.
83. Lung Health Study Research, Group Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000, 343:1902-1909.
84. Pauwels R.A., Lofdahl C.G., Laitinen L.A., Schouten J.P., Postma D.S., Pride N.B., et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999, 340:1948-1953.
85. Chambellan A., Chailleux E., Similowski T. Prognostic value of the hematocrit in patients with severe COPD receiving long-term oxygen therapy. Chest 2005, 128:1201-1208. ANTADIR Observatory Group.
86. Mannino D.M., Shorr A.F., Doyle J.J., Stern L.S., Dolgister M., Siegartel L.R., et al. Prevalence of anemia in subjects with chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006, 3:A615.
87. Halpern M.T., Zilberberg M.D., Schmier J.K., Lau E.C., Shorr A.F. Anemia, costs and mortality in Chronic Obstructive Pulmonary Disease. Cost Eff Resour Alloc 2006, 4:17.
88. John M., Lange A., Hoernig S., Witt C., Anker S.D. Prevalence of anemia in chronic obstructive pulmonary disease: comparison to other chronic diseases. Int J Cardiol 2006, 111:365-370.
89. De Miguel Díez J., Chillón Martín M.J., Méndez Bailón M., Álvarez-Sala J.L. Impacto de la anemia en la EPOC. Arch Bronconeumol 2009, 45(Supl. 4):47-50.
90. John M., Lange A., Hoernig S., Witt C., Anker S.D. Prevalence of anemia in chronic obstructive pulmonary disease: comparison to other chronic diseases. Int J Cardiol 2006, 111:365-370.
91. Celli B.R., Cote C.G., Marín J.M., Casanova C., Montes de Oca M., Méndez R.A., et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004, 350:1005-1012.
92. Schonhofer B., Wenzel M., Geibel M., Kohler D. Blood transfusion and lung function in chronically anemic patients with severe chronic obstructive pulmonary disease. Crit Care Med 1998, 26:1824-1828.
93. Schonhofer B., Bohrer H., Kohler D. Blood transfusion facilitating difficult weaning from the ventilator. Anaesthesia 1998, 53:181-184.
94. López García F., Pineda Cuenca M., Custardoy Olavarrieta J. Ansiedad y depresión en la EPOC. Rev Clin Esp 2007, 207(Supl. 1):53-57.